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P. R. Bartel, J. Verster, P. J. Becker
Polysomnograms have been recorded at our laboratory
since 1985 for the diagnosis of sleep apnoea. Until the
recent availability of continuous positive airway pressure
devices in Johannesburg, it appeared that some of our
subjects were receiving only conservative or no treatment.
Structured interviews were conducted with 63 patients
with positive polysomnographic findings of sleep
apnoea/hypopnoea (SAH), and, where possible, with
sleeping partners. Infonnation was obtained about the
patients' understanding of the diagnosis by the referring
doctor, the recommended treatment and psychosocial
consequences. The primary reason for the initial
consultation was excessive daytime sleepiness (43%).
Diagnoses following polysomnography included SAH
(65%) and .narcolepsy (6%), while 10% were told they had
nothing to be concerned about. Some fonn of treatment
was recommended to 80% of patients, usually weight loss
(60%) or medication (59%). Psychosocial consequences
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were prominent and included a perception of reduced
work capacity (62%) and compromised safety (56%). At the
time of the interview 90% of patients were experiencing
one or more symptoms associated with SAH. These
findings support the serious nature of SAH and conftnn
the need for adequate treatment centres in South Africa.
S Afr Med J 1995; 85: 874-877.
Sleep apnoea is the cessation of, or a more than 90%
decrease in, baseline airflow at the nose.or mouth for a.
period of 10 seconds or longer. Sleep hypopnoea involves a
more than 50% but less than 90% decrease in airflow
associated with awakening, signs of EEG arousal or a more
than 3% decrease· in oxyhaemoglobin saturation determined
by oximetry.' There is a lack. of uniformity in the number of
these events per sleep period which constitutes a..dondition
of clinical significance. Criteria of 5 events per hour of sleep
or 10 events per hour have been applied! When th~se
repetitive disruptions of breathing during sleep aref
associated with one or more symptoms such as excessive
daytime somnolence, loud snoring, unsatisfying nocturnal
sleep, disrupted sleep or secondary polycythemia, this
condition is referred to as the sleep apnoea/hypopnoea
syndrome (SAHS).3 However, many other symptoms may be
reported. .
Diagnostic problems are common and, even in severe
cases, diagnosis may be delayed for years because the
patient's daytime symptoms are highlighted. SAHS is
frequently missed as a result of diffuse symptoms, and
patients tend to be referred to a series of different
specialists.4 Even clinicians with experience in sleep
disorders may only be able to predict sleep apnoea in 50%
of patients suspected of having this disorder when relying
on clinical features such as history, physical examination
and subjective impressions.5 A laboratory test, the
polysomnogram, frequently provides vital diagnostic
information, including the type and severity of SAH, and the
findings may have therapeutic implications.6
Several different approaches to treatment have been.
advocated. Weight loss and other behavioural strategies,
continuous positive airway pressure (CPAP) therapy and
surgery are the most common for obstructive SAH.6 In
central SAH, which is much less prevalent than obstructive
SAH, medication is the most common form of treatment but
usually has limited efficacy.7
SAHS is relatively common, occurring in approximately
1 - 8% of adult males"·'o The condition occurs much. less
frequently in women."
Our unit has offered a polysomnographic service since
1985. From informal, occasional contact with patients we
gained the impression that either conservative or no
treatment may have been a typical approach. CPAP therapy
has only recently become available in Johannesburg and
was not used by our patients.
This study sought to obtain information on the effects of
treatment on SAHS and the progression of symptoms in
patients likely to be receiving conservative treatment.
Previous studies of this kind are rare and African studies
have not been reported.
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Material and methods Table I. Primary reason given by patients for consulting the
doctor who recommended the polysomnographic test
Reason No. %
Treatment Group Complying Benefiting
Table 11. Patients' reports regarding treatment(s) recommended by
the referring doctor (%)
Weight reduction 60 71 59
Medication 59 100 30
Change of sleep position 16 77 57

























Other reasons (e.g. asthma)
Following the positive polysomnographic findings of SAH,
patients claimed that they were given the following
diagnosis: 65% sleep apnoea, 6% narcolepsy, 2% a
dysfunction of a gland in the brain; 10% were told that they
had no medical problem to be concerned about. No
diagnosis was given to 18%, but they were referred to
another doctor.
Treatments recommended to the patients are summarised
in Table 11. Most frequently advocated was weight loss (60%
of the group). Of these patients 71 % claimed to have
managed to lose weight at some stage and just over half of
these patients felt that they had experienced some
alleviation of their symptoms as a result. Notwithstanding
this, 67% of patients exceeded 130% of their ideal weight at
the time of the interview and only 9% were within 10% of
their ideal weight. Seven patients exceeded 200% of their
ideal weight. Of our patients who reported having
succeeded in losing weight, the amount lost varied from 5
kg to 76 kg with a mean of 20 kg.
Structured telephonic interviews were conducted with 63
patients whose polysomnographic findings were indicative
of SAH. Where possible, information was also obtained from
spouses, who were the sole source of information in the
case of the 7 patients who were deceased at the time of the
interview.
Polysomnographic recordings commenced between
13hOO and 14hOO and lasted for 2 - 3 hours. The majority of
patients were regarded as having sleep apnoea if they
experienced five or more periods of apnoea per hour of
non-rapid eye movement sleep, each period exceeding
10 seconds in duration. Only latterly was sleep hypopnoea3
taken into account. Oxygen saturation levels were monitored
by pulse oximetry in a minority of the latter subjects.
Polysomnographic findings indicated that 27% of subjects
had obstnuctive SAH, 25% had central and 48% had mixed
SAH. The use of afternoon polysomnographic recordings
probably identified subjects at the severe end of the SAHS
spectnum and is likely to have exaggerated the incidence of
central SAH.
There were 57 men and 6 women, aged 28 - 69 years
(mean 49 years). The period between diagnostic test and
interview was 1 month to 7 years (mean 1,9 years). There
were 62 white subjects and 1 Asian. The mean body mass
index'2 was 34 (range 18 - 78). The occupations of patients
covered a broad spectrum from manual worker to highly
qualified professional.
The interview requested information on: (I) the main
reasons for consulting the doctor who then requested the
polysomnogram; (iI) perception of the diagnosis by the
referring doctor; (ib) details of treatment instituted by the
referring doctor and its effectiveness; (iv) the time-course of
symptoms related to SAHSand their presence at the time of
the interview; (v) additional medical problems possibly
related to SAHS; and (VI) the psychosocial effects of SAHS,
including those related to work and safety and family
relationships. Responses were coded for analysis by
computer.
Results
Of the 7 deceased patients, 1 had died during sleep;
narcolepsy had been given as the cause on the death
certificate. Another died of a heart attack, 1 as a result of
complications following gastric stapling, 1 from cancer and
2 from unknown causes, according to their spouses.
Almost half (48%) of the patients were referred for
polysomnography by neurologists, 25% by specialist
physicians and the remainder by other specialists including
otolaryngologists and psychiatrists. Only 2 patients were
referred by general practitioners.
The main reasons for seeking medical treatment are
summarised in Table I. Excessive daytime sleepiness was
most frequently mentioned (43%). Diverse medical problems
such as hypertension and asthma were predominant in 24%
of patients. Only 6% of patients suspected a sleep-related
breathing problem, usually as a result of observations by the
sleeping partner.
A change in sleeping position, usually to avoid sleeping on
the back, was recommended to 16% of patients. This was
attempted by 77% of these patients and 57% of them
claimed that it had helped to a noticeable degree.
Some form of surgery was recommended to 13 patients
(24%). Six patients refused, 2 patients underwent gastric
stapling for severe obesity and 4 had operations to the
throat. Only 1 patient claimed to have benefited from the
surgery.
While 59% of patients reported that their referring doctors
had prescribed medication, these details tended to be
vague. Thirty per cent reported that they had been
prescribed a stimulant, 10% a hypnotic and 3%
antidepressants. The majority of these patients (60%)
claimed to have derived no benefit from the medication.
Following diagnosis, 38% of patients revisited their
referring doctor, 33% sought no further medical advice and
29% changed doctors. The reasons for seeking further
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Symptoms No. %
Discussion
Table IV. Typical symptoms of SAH reported by patients to be
present at the time of the interview IN =63)
Table Ill. Patients' views on the course of symptoms following the
polysomnographic test IN =62)
A number of our patients specifically mentioned having
experienced motor vehicle accidents and, in some cases,
multiple accidents. Falling asleep while driving is a common
experience in SAHS.
There seems to be a widespread opinion that appreciable
weight loss is difficult for patients with SAHS to achieve and
maintain. There were, however, a few successful patients
who claimed marked beneficial effects. Nevertheless,
obesity was a prominent feature in our group of SAHS
patients. At the time of assessment 67% were more than
130% of their ideal weight and this despite attempts at
weight loss by a substantial proportion of patients. This is
comparable with the 69% in a Scottish group at the time of
diagnosis and before the commencement of treatment. 14
The small number of patients undergoing surgery does not
permit any assessment of its effectiveness. Of 13 patients
who were advised to undergo gastric stapling or throat
surgery, 6 refused. ClearJy, surgery is an option for s.6me
patients and a tracheostomy may be necessary in severe
cases of obstructive SAH.7 .
Potential difficulties in the diagnosis of SAHS witt1~ut the
aid of a polysomnogram are evident in the finding that only
approximately half of the patients mentioned one or more of
the typical symptoms of SAHS as their main reason for
seeking medical assistance. Only 6% of patients suspected
a sleep-related breathing disorder. The suspicion of SAHS
appeared to emerge during the history-taking by the doctor
and led to the request for a polysomnogram.
Following positive polysomnographic findings of SAHS,
65% of patients reported that they understood their
diagnosis to include a sleep-related breathing disorder.
However, many patients expressed dissatisfaction with a
perceived lack of interest in their condition and tended to
consult several specialists. Despite positive
polysomnographic findings, 10% of patients claimed to have
been told that their condition was not a cause for concern
and did not require further attention.
While little is currently known about long-term morbidity
and mortality in obstructive SAH,,5 the importance of
effective treatment is supported by previous studies.,·,'7
After a 7-year follow-up, 12% of conservatively treated
patients, who had received a weight-loss recommendation
only, "had suffered either myocardial infarction or stroke. In a
comparable group in terms of age, body mass index and
apnoea index, but on whom tracheostomies had been
performed, only 3% had experienced one of these. Mortality
rates at 11-year follow-up showed distinct benefits for the
tracheostomised group. Another study reported no
significant differences in survival between tracheostomised
patients with obstructive SAH and normal controls over 5-
and 10-year periods.'· This is further evidence that active
treatment decreases cardiovascular mortality.'o
Our patients often reported declining work performance.
While daytime sleepiness is a likely factor, the effects of
nocturnal hypoxaemia on brain function might be another
factor. There is evidence of possible irreversible cognitive
decline in some cases of severe SAHS.'9
There seems to be little doubt that specialised centres,
which offer diagnostic and treatment services to patients
with SAHS, are needed. Failure to provide this service
prolongs exposure to a potentially debilitating condition and

















Daytime sleepiness 47 77
Snoring 50 81
Disturbed nocturnal sleep 32 53
Obesity 47 74
Morning headaches 19 31
Swollen ankles 30 49
Hypertension 29 46
Pulmonary dysfunction 11 18
Almost half the patients (46%) were aware of being
hypertensive, and 6% had experienced a stroke during the
period between the polysomnogram and the interview.
Negative effects on work performance were claimed by
62% of patients and 56% had experienced compromised
safety, particularly when driving a motor vehicle.
Negative effects on general social relationships were
reported by 64% of patients and specifically within the
family by 41%.
treatment were diverse and in only 25% of these patients
were the reasons apparently directly related to SAHS.
From the time of the polysomnogram, 40% of patients
thought their symptoms related to SAH had remained
unchanged, 26% noted a slight improvement, 18% a
definite improvement, 5% a slight deterioration and 11 % a
definite deterioration (fable Ill).
Symptoms typically associated with SAHS at the time of
the interview are summarised in Table IV. Altogether 90% of
the patients were experiencing one or more symptoms of
SAHS.
An important finding of this study relates to the limited
efficacy of the conservative treatment of SAHS. Only 16% of
patients reported a definite improvement in symptoms, but
at the time of the interview 90% were still experiencing
symptoms that could be related to SAHS.
Daytime sleepiness was being experienced by 77%. This
symptom is recognised as detrimental to the well-being of
the patient, it reduces work efficiency and it increases the
likelihood of traffic accidents. Daytime sleepiness is
important in the context of increasing demands on efficiency
and maintained vigilance in the work situation and in the
commonly encountered increased traffic volumes.'3
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driving a motor vehicle. In addition, patients with this
potentially reversible condition often perform poorly in the
work situation and experience negative changes to family
relationships. A failure to treat this condition is likely to have
major medical and social consequences.
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Evaluation of the World
Health Organisation'
antibody-testing strategy
for the individual patient
diagnosis of HIV infection
(strategy Ill)
D. J. Martin, N. K. Blackburn, K. F. O'Connell,
E. T. Brant, E. A. Goetsch
Objective. To evaluate the World Health Organisation
(WHO) antibody testing strategy for the individual patient
diagnosis of HIV infection (strategy Ill).
Design. Evaluation of a combination of enzyme-linked
immunosorbent assays (ELlSAs) for the detection of
antibodies to HIV-1 and HIV-2 infection. The WHO strategy
III calls for a combination of three ELlSAs, based on
different antigens and/or differing test principles, to be
used in a sequential fashion. The first part of the study
evaluated various kits as part of a selection process. The
second part of the study was an assessment of the three-
ELlSA testing strategy on routine sera submitted to the
National Institute for Virology (NIV) for HIV testing. In all
instances, the conventional testing protocol, which utilises
a screening ELlSA followed by a confirmatory Western
blot (WB) on positive specimens, was used as the 'gold
standard'.
Setting. The HIV-testing laboratory at the NIV,
Johannesburg.
Results. In the first part of the study, all of the ELlSA kits
evaluated showed high sensitivity and specificity, and a
selection of the kits for part two of the study was made in
accordance with the WHO recommendation. The kits
selected, in order of use, were the Biotest anti-HIV 1/2
(test 1), Pasteur Genelavia Mixt HIV-1/2 (test 2) and Murex
Wellcozyme HIV-1 competitive assay (test 3). This
combination was evaluated using 7 812 sera submitted to
the NIV for serology testing. The sensitivities of the tests
were highly satisfactory (99,6 - 100%) as' were the
specificities (99,2 - 100%). The positive predictive value of
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